Cancer Management and Research (Sep 2019)
rhTPO combined with chemotherapy and G-CSF for autologous peripheral blood stem cells in patients with refractory/relapsed non-Hodgkin’s lymphoma
Abstract
Jun Zhu,1 Si-Guo Hao,2 Jiong Hu,3 Jing-Li Zhuang,4 Chun Wang,1 Hai-Tao Bai1 1Department of Haematology, Shanghai General Hospital, Shanghai 200080, People’s Republic of China; 2Department of Haematology, Shanghai Jiaotong University Affiliated Xinhua Hospital, Shanghai 200092, People’s Republic of China; 3Department of Haematology, Shanghai Jiaotong University Affiliated Ruijing Hospital, Shanghai 200020, People’s Republic of China; 4Department of Haematology, Fudan University Affiliated Zhongshan Hospital, Shanghai 200032, People’s Republic of ChinaCorrespondence: Chun Wang; Hai-Tao BaiDepartment of Haematology, Shanghai General Hospital, No. 100 Haining Road, Hongkou District, Shanghai 200080, People’s Republic of ChinaTel +86 216 324 0090; +86 216 324 0090-3171Fax +86 213 779 8078Email [email protected]; [email protected]: The mobilization and collection of sufficient autologous peripheral blood stem cells (APBSCs) are important for the fast and sustained reconstruction of hematopoietic function after autologous transplantation. This study aims to evaluate the mobilization effect and safety of thrombopoietin (TPO) combined with chemotherapy + G-CSF for APBSCs in patients with refractory/relapsed non-Hodgkin’s lymphoma.Methods: A total of 78 patients were included in the present study. After receiving mobilization chemotherapy, all patients were randomly divided into two groups: TPO group (n=40), patients were given subcutaneous injection of rhTPO + G-CSF, and control group (n=38), patients were given subcutaneous injection of G-CSF. The primary endpoint was the total number of obtained CD34+ cells. The secondary endpoints were the mononuclear cell count, the proportion of target and minimum mobilization, the engraftment time of neutrophils and platelets after APBSCT, the number of platelet and red blood cell infusions, the incidence of infectious fever and fever duration, and TPO-related side effects in patients.Results: TPO participation significantly increased the total CD34+ cell count. A higher proportion of patients in the TPO group achieved the minimum and target CD34+ cells, when compared to the control group. TPO-related adverse events were not observed in either of these groups. In addition, there were no significant differences in engraftment time, the number of platelet and red blood cell transfusions, the incidence of infectious fever, and fever duration between these two groups.Conclusion: TPO combined with chemotherapy + G-CSF can safely and effectively enhance the mobilization effect for APBSCs in patients with refractory/relapsed non-Hodgkin’s lymphoma.Keywords: recombinant human thrombopoietin, mobilization, non-Hodgkin’s